Join
Live feed
·
PRReleasevia Quantisnow
Pliant Therapeutics Inc. logo

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

ByQuantisnow·Wall Street's wire, on your screen.
PLRX· Pliant Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PLRX (Pliant Therapeutics Inc.) and more on Quantisnow.